Trade Report: The California State Teachers Retirement System decides to keep it stake in Adamas Pharmaceuticals Inc. (ADMS) to the level of $530,000

The California State Teachers Retirement System decides to keep it stake in Adamas Pharmaceuticals Inc. (ADMS) to the level of $530,000

California State Teachers Retirement System increased its position in shares of Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) by 35.6% during the second quarter, Holdings Channel reports. The institutional investor owned 35,014 shares of the specialty pharmaceutical company’s stock after buying an additional 9,184 shares during the period. California State Teachers Retirement System owned 0.16% of Adamas Pharmaceuticals worth $530,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of ADMS. Bank of New York Mellon Corp raised its stake in shares of Adamas Pharmaceuticals by 21.8% in the second quarter. Bank of New York Mellon Corp now owns 60,282 shares of the specialty pharmaceutical company’s stock worth $912,000 after buying an additional 10,802 shares in the last quarter. Emerald Mutual Fund Advisers Trust raised its stake in shares of Adamas Pharmaceuticals by 4.0% in the second quarter. Emerald Mutual Fund Advisers Trust now owns 559,879 shares of the specialty pharmaceutical company’s stock worth $8,477,000 after buying an additional 21,301 shares in the last quarter. Cheyne Capital Management UK LLP raised its stake in shares of Adamas Pharmaceuticals by 109.6% in the second quarter. Cheyne Capital Management UK LLP now owns 114,765 shares of the specialty pharmaceutical company’s stock worth $1,737,000 after buying an additional 60,000 shares in the last quarter. Alps Advisors Inc. raised its stake in shares of Adamas Pharmaceuticals by 26.1% in the second quarter. Alps Advisors Inc. now owns 30,382 shares of the specialty pharmaceutical company’s stock worth $460,000 after buying an additional 6,296 shares in the last quarter. Finally, Opaleye Management Inc. raised its stake in shares of Adamas Pharmaceuticals by 68.4% in the first quarter. Opaleye Management Inc. now owns 320,000 shares of the specialty pharmaceutical company’s stock worth $6,064,000 after buying an additional 130,000 shares in the last quarter. Hedge funds and other institutional investors own 74.65% of the company’s stock.

Shares of Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) traded down 0.41% during trading on Friday, reaching $15.94. 170,276 shares of the company were exchanged. The stock has a 50-day moving average price of $15.78 and a 200-day moving average price of $15.77. Adamas Pharmaceuticals Inc. has a one year low of $12.02 and a one year high of $31.84. The stock’s market capitalization is $349.55 million.

A number of analysts have weighed in on the stock. Mizuho restated a “buy” rating and issued a $26.00 target price on shares of Adamas Pharmaceuticals in a research report on Friday, September 23rd. Noble Financial assumed coverage on shares of Adamas Pharmaceuticals in a research report on Friday, June 17th. They issued a “buy” rating and a $25.00 target price on the stock. Credit Suisse Group AG restated a “buy” rating on shares of Adamas Pharmaceuticals in a research report on Wednesday, June 22nd. JMP Securities restated a “buy” rating on shares of Adamas Pharmaceuticals in a research report on Wednesday, June 15th. Finally, Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $44.00 price target on shares of Adamas Pharmaceuticals in a research note on Tuesday, June 14th. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $32.11.

In other news, major shareholder Ix Lp Mdv bought 62,977 shares of the firm’s stock in a transaction that occurred on Friday, September 16th. The shares were acquired at an average price of $16.48 per share, with a total value of $1,037,860.96. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director William W. Ericson bought 7,200 shares of the firm’s stock in a transaction that occurred on Tuesday, September 6th. The shares were purchased at an average cost of $15.00 per share, for a total transaction of $108,000.00. The disclosure for this purchase can be found here. Corporate insiders own 31.79% of the company’s stock.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems (CNS). Its segment focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous system.

Related posts

Leave a Comment